ATLANTA, Sept. 7, 2006 (PRIMEZONE) -- Bio-Matrix Scientific Group Inc. (OTCBB:BMSN) announced that the company is now profiled on Market-Pulse.com. Bio-Matrix Scientific Group is a development stage company engaged in biotech research. Bio-Matrix is engaged in the cryogenic storage of non-controversial stem cells and development of medical devices used in live tissue transfer and stem cell research. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Market Pulse's profile focuses on the company and its products, the industry and markets, leadership, recent developments and the future. Individuals interested in more information on the company can view the profile at http://www.market-pulse.com/thiiprofile.htm
Bio-Matrix has developed approximately 192 disposable instruments for use in plastic surgery, tissue management and stem cell research. These instruments have been designed to harvest adult stem cells from adipose tissue (extracted primarily during liposuction procedures). Due to the increasing number of liposuctions in the U.S., there should be a significant demand for the processing and storage of stem cells from fat tissue. Bio-Matrix may become the first company to operate an adipose-derived stem cell bank in the U.S.
According to Bernard R. Schmitt, CEO of Market Pulse, "We are very excited to introduce Bio-Matrix Scientific Group Inc. to the investment community. Bio-Matrix has made excellent fundamental strides over the last few months. The company's new 15,000-sq.-ft., state-of-the-art facility, located in the heart of San Diego, will house the nation's premiere center for stem cell storage." Bernard Schmitt also noted that, "BMSN seeks to improve on its innovative therapies and its state-of-the-art facilities to grow its market position in the $75 billion biotech and medical device industry. This little known company could be the next discovered gem in this industry."
Bio-Matrix has a four pronged revenue strategy, each with a different trajectory but essentially meeting the company's core objectives of developing or acquiring patented or proprietary technology that can be converted into a steady revenue stream, either by manufacturing products or licensing the technology. Management expects to realize a total of approximately $4 million for its stem cell banking operations in 2007 itself. In the years 2008 and 2009, this operation is expected to yield revenues of approximately $14.07 million and $26.22 million, respectively. Bio-Matrix Scientific Group recently was rated "Outperform" with a target price of $6.00 by Beacon Equity Senior Research Analyst, Kris Goldcross, CFA.
Bio-Matrix recently installed a CBS Isothermal liquid nitrogen vapor storage tank and a K Series cryo-storage tank for stem cell storage. The company will utilize the new CBS V5000 cryo-tank as the flagship for cellular storage at the facility. This new technology will validate central liquid nitrogen supply that feeds all units housed at the Bio-Matrix facility.
Bio-Matrix Scientific Group Managing Director and COO Brian Pockett stated, "An investment in this new, V-5000 Isothermal Liquid Nitrogen tank and K Series tank allows Bio-Matrix to enter into system testing, which will lead to accepting stem cell storage. This is an important step toward establishing the company's Good Manufacturing Practices (cGMPs) and Good Tissue Practices (cGTP) quality systems which is an important part of our facility master validation plan that will enhance our ability to provide superior stem cell storage over the long term." The company expects to open the facility for business by the end of September 2006, anticipating revenue in the fourth quarter of 2006.
About Bio-Matrix Scientific Group Inc.
Bio-Matrix Scientific Group Inc., a Nevada corporation, is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Other companies in the same industry as Bio-Matrix Scientific Group Inc. are StemCells Inc., Thermogenesis Corporation and Regeneration Technologies Inc.
About Market Pulse
Market Pulse LLC, the owner and operator of Market-Pulse.com (collectively referred to as "MP"), is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. MP is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. MP's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. MP provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. MP offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.market-pulse.com.
Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
MP, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.
You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: Bio-Matrix Scientific Group Inc. compensation from a third party shareholder: twenty five thousand free trading shares of stock in Bio-Matrix Scientific Group Inc., already delivered from a third party shareholder. To date, MP has sold zero shares of stock in Bio-Matrix Scientific Group Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services.